In the manuscript by Clot et al., 39 nodal MCL patients (62% belonging to high-risk MIPI group- exactly the same number as in our own analyzed cohort) were analyzed for TP53 aberration and CDKN2A deletion (besides other analyzed genes) [17]. This evidence concerns the gene TP53 and mantle cell lymphoma.